Related Experiment Video
Updated: Aug 14, 2025
Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
Published on: July 17, 2020
Alpelisib Efficacy without Cherry-PI3King Mutations
1Department of Molecular and Systems Biology, Dartmouth Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire.
Abstract:
The PI3K inhibitor alpelisib is clinically approved for the treatment of metastatic estrogen receptor-positive breast cancers harboring hotspot mutations in PIK3CA, which encodes a subunit of PI3K. Prospective clinical trial results demonstrated benefit from alpelisib for the treatment of advanced ER+ breast cancers harboring PIK3CA mutations in the hotspots of exons 7, 9, and 20. However, 20% of PIK3CA mutations occur in non-hotspot regions. A recent article demonstrated that patients with cancers bearing non-hotspot PIK3CA mutations also derived benefit from alpelisib, which will inform clinical decision-making moving forward. See related article by Rugo et al., p. 1056.
Insights
The PI3K inhibitor alpelisib benefits patients with advanced estrogen receptor-positive breast cancer. This includes cancers with PIK3CA mutations in non-hotspot regions, expanding treatment options.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Alpelisib is approved for metastatic estrogen receptor-positive (ER+) breast cancer with PIK3CA hotspot mutations.
- PIK3CA mutations are found in hotspot regions (exons 7, 9, 20) and non-hotspot regions.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
